Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2023, Poseida Therapeutics, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following proposals and cast their votes as set forth below. A more detailed description of each proposal is set forth in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 26, 2023.

Proposal 1. Election of Directors

The Company's stockholders elected each of the individuals listed below as Class III Directors, to serve until the Company's 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal. The final voting results are as follows:


                                  For        Withheld    Broker Non-Votes
Rafael G. Amado, M.D.          66,413,731     143,161            8,072,510
Charles M. Baum, M.D., Ph.D.   58,547,680    8,009,212           8,072,510

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company's Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows:



    For       Against    Abstain
 74,531,018     85,378     13,006

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses